Emoxypine - Algernon Health
Alternative Names: NP-178Latest Information Update: 23 Oct 2025
At a glance
- Originator Nash Pharmaceuticals
- Developer Algernon Health
- Class Anti-inflammatories; Antidepressants; Antiglaucomas; Anxiolytics; Heart failure therapies; Nootropics; Pyridines; Small molecules
- Mechanism of Action Antioxidants; NF-E2-related factor 2 modulators
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Crohn's disease; Ulcerative colitis